Are these penny stocks on your list right now?
The post 3 Penny Stocks Worth Watching This Week appeared first on Penny Stocks to Buy, Picks, News and…
Best Penny Stocks to Watch During Trading This Week
After another interesting day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have several factors that are causing movement with penny stocks. And all of this has caused another day of decent losses across the board. While this is a difficult sentiment for investors to come to terms with, it could also present opportunities for traders to profit. Today, we saw the S&P 500 slide by around 1.3% with the Dow Jones dropping 150 points.
One of the biggest drops of the day came from Snap Inc. (NYSE: SNAP), which fell by more than 40% at EOD. This brought many tech stocks down with it, which is disheartening. So, while all of this has served to create a tough investing environment, we do know that the volatility we’re witnessing is characteristic of what we’ve seen in the past few weeks. Considering all of this, let’s take a look at three penny stocks that climbed during trading today.
3 Penny Stocks That Gained During Trading on May 24th
While GOVX stock managed to climb during intraday trading, it took a dive alongside the rest of the stock market at EOD. Despite this, in the past five days, shares of GOVX stock have shot up by a staggering 241%. To understand why we are seeing this major gain, we have to take a closer look at the company and any recent announcements from it. The biggest recent news came today when the company announced the notice of allowance for a cancer vaccine patent in China.
“This patent allowance complements the previously issued U.S. Patent No. 11278607, demonstrating the global importance of this technology, and adding to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families. GeoVax is committed to advancing meaningful cancer immunotherapies towards improving the lives of patients worldwide.”
The CEO of Geovax, David Dodd
This is great news for the company despite its fall during intraday trading. And, in addition to its work on this, GOVX has a role in preventing Covid-19, making it an interesting penny stock right now. Whether it deserves a spot on your list of penny stocks to watch however, is up to you.
DiDi Global Inc. (NYSE: DIDI)
By EOD on May 24th, shares of DIDI stock shot up by around 2.7%. While this is nothing to write home about, it is significant considering the rest of the market’s trajectory during that time. In addition to this, shares of DIDI have fallen by around 17%, which makes today’s uptick even more important. To understand why, we can look at an announcement made by the company on May 23rd.
On the 23rd, it stated that it has secured approval from its shareholders to delist from the NYSE. The majority of this sentiment comes from the goal of resolving a cybersecurity probe that the company has been going through in China. This has resulted in a drop of around $70 million from the market value of DiDi throughout the length of the probe. And, many investors are seeing an end in sight now that this delisting is fully on the table. Considering all of that, will DIDI be on your penny stocks watchlist or not?
Scisparc Ltd. (NASDAQ: SPRC)
Another major gainer of the day on Tuesday, May 24th is SPRC stock, which shot up by over 22% at EOD. This sizable uptick brings shares of SPRC stock to around $2.80, which is the result of news announced today. The company stated that its joint pre-clinical trial with Clearmind Medicine Inc. has shown positive results. This is regarding its psychedelic combination treatment, which is a big breakthrough for the company.
“We are pleased with these latest results that confirm the high safety profile of the psychedelic combination treatment. Previous testing results showed high efficacy potential in treating alcoholism when using this combination. We plan on further exploring the safety and efficacy of combining our technology with Clearmind’s novel molecule.”
The Chief Executive Officer of Scisparc, Oz Adler
In results released previously, the company did show that this treatment reduced alcohol consumption in animals. Right now, we are seeing a major emphasis on biotech penny stocks. And because of that, companies like SPRC are receiving more attention than usual. While it is tough to say if this will continue, it is clear that SPRC is making big headway right now. And, when we see announcements like this, it is crucial to pay attention to the company and what it could do in the future. Considering that, do you think SPRC is a buy or not?
Which Penny Stocks Are You Watching Right Now?
Finding the best penny stocks to buy right now is challenging. And with so much going on in the stock market, it is as easy to lose money with penny stocks as it is to make money. So, keeping that in mind, trading right now is all about understanding how to take advantage of the current state of the stock market.
As you may know, the largest causes of movement in the stock market right now include rising interest rates, climbing inflation, Covid, Monkeypox, and more. And as a result of all of this, we expect volatility to continue. So, with this in mind, which penny stocks are you watching right now?
Best Stocks To Buy Today? 3 Travel Stocks in Focus
Check out these travel stocks as China loosens its lockdown restrictions.
The post Best Stocks To Buy Today? 3 Travel Stocks in Focus appeared first on…
As we’re approaching Independence Day, travel stocks may seem attractive for investors today. Since parts of the world are already moving towards the endemic phase, consumers could be increasingly keen on traveling. Moreover, with summer vacations continuing, families are excited to enjoy a vacation somewhere in the world. According to an estimate by the American Automobile Association, 42 million Americans are likely to travel for the long weekend ahead. Therefore, it would make sense that investors are considering travel stocks now.
On top of that, China has just cut the quarantine period for international travelers. This would make for a milestone in its loosening of Covid restrictions in the past two years. According to the revised government protocol, international travelers only have to quarantine at centralized facilities for seven days, and an additional three days spent at home before venturing out. This decision is made as Chinese officials continue to get a hold of the pandemic locally.
The slash in quarantine times has benefited many companies, and Wynn Resorts (NASDAQ: WYNN) and Las Vegas Sands (NYSE: LVS) are some of them. Since both companies operate casinos in Macau, both companies are gaining in the stock market today. Evidently, both LVS stock and WYNN stock are now gaining by over 7% at the opening bell today. With a great weekend coming ahead, here are three more travel stocks for your watchlist today.
First up on our list today we have an international online travel agency, Trip.com. In short, the company offers hotel reservations, flight tickets, package tours, corporate travel management, and train ticketing services. All of which are readily available to consumers via its one-stop mobile app. With hotel and transportation information given, leisure and business travelers can make reservations. Travel packages and guided tours are also offered for corporate clients to manage their travel needs. For independent leisure visitors, Trip.com also provides package trips, including those for tour groups, semi-tour groups, and private groups.
Source: TD Ameritrade TOS
Yesterday, Trip.com released its first fiscal quarter financial results. Among its highlights, net revenue was $649 million, remaining stable year-over-year. The reason is because of the impact of the latest wave of Covid in China. However, staycation travels have been a major contributor to the recovery of the Chinese domestic market. In particular, local hotel bookings are up by over 20% year-over-year. At the same time, Trip.com’s air-ticket bookings on its global platforms are also up by 270% over the same period.
Despite China’s strict lockdown measures in most of the first half of 2022, Trip.com is maintaining its overall growth. According to CEO Jane Sun, the company’s “results demonstrated our resilience amidst a confluence of challenges and uncertainties.” Sun also adds, “While we may continue to see short-term fluctuations, demand for travel is still strong and shows a bright outlook in the long-term.” Pair all this with China loosening its restrictions and TCOM stock could be an attractive buy amongst its travel stock peers. Would you say the same?
Next, we have Spirit Airlines, an ultra-low-cost carrier. The company operates across the U.S., Latin America, and the Caribbean. In fact, it is a leader in providing customizable travel options that start with an unbundled fare. Its Fit Fleet is one of the youngest and most fuel-efficient in the U.S. as well. In recent weeks, the company has been locked in a fierce battle as companies like JetBlue (NASDAQ: JBLU) and Frontier Group (NASDAQ: ULCC) have been trying to bid for Spirit.
The saga could be heading towards a climax this week as Spirit shareholders will vote on fellow budget airline Frontier’s acquisition offer on Thursday. However, JetBlue has been on the offensive, even boosting its offer price for Spirit on Monday evening. Diving in, JetBlue’s new offer raises the reverse break-up fee to $400 million from $350 million if regulators do not approve the deal. It also includes a dividend to Spirit shareholders of $2.50 a share, up from its previous offer of $1.50. On Frontier’s end, however, the company dismissed JetBlue’s claims that its acquisition of Spirit will lead to lower airfares.
Separately, TIG Advisors, an investment adviser that owns a stake of approximately 2 million Spirit Airlines shares, says that it has just sent a letter to the board of directors at Spirit regarding its intention to vote against the company’s proposed merger agreement with Frontier Group. It believes that its merger with JetBlue is the far superior outcome for Spirit shareholders due to its all-cash bid. This would also eliminate execution risk and maximize certainty of value. All things considered, should investors be looking at SAVE stock right now?
Topping our list today, we have Airbnb, a travel company that offers an online marketplace for lodging and tourism activities. It mainly earns its income through commissions from each booking. Today, it has over 4 million hosts who have welcomed more than 1 billion guests across the globe.
Today, the company announced that it is officially codifying the ban of all parties and events in its listings as part of its policy. This follows a temporary ban that was initiated in August 2020 on all parties and events. In that time since the company says it saw a direct correlation between the implementation of its policy in August 2020 and a 44% year-over-year drop in the rate of party reports. The ban has also been well received by its host community and it has also received positive feedback from community leaders and elected officials.
On June 27, 2022, the company also reported that family travel and long-term stays will trend across the U.S. this Independence Day. For instance, from February 2022 to March 2022, searches for stays over July 4th have increased by nearly 50%. Also, hosts could stand to earn a lot during the holiday. After all, last year’s Independence Day yielded the biggest payout for U.S. hosts in 2021 compared to other holiday weekends, a major moment for hosts to earn. All things considered, is ABNB stock worth investing in right now?
Source: TD Ameritrade TOS
If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel.
CLICK HERE RIGHT NOW!!
Maternal mortality jumped during COVID-19 pandemic
The COVID-19 pandemic and its impacts have taken a disproportionate toll on American mothers who were pregnant or just gave birth. Maternal mortality (i.e.,…
The COVID-19 pandemic and its impacts have taken a disproportionate toll on American mothers who were pregnant or just gave birth. Maternal mortality (i.e., deaths during pregnancy or in the early postpartum period) increased by 18% in 2020, according to data from the National Center for Health Statistics, exceeding the ~16% increase in overall US mortality in 2020. Yet according to a new analysis from the University of Maryland and Boston University, the maternal death rate after the start of the COVID-19 pandemic was even higher, and disproportionately impacted Black and non-white Hispanic mothers.
Credit: Marie E. Thoma, PhD; Eugene R. Declercq, PhD in JAMA Network Open
The COVID-19 pandemic and its impacts have taken a disproportionate toll on American mothers who were pregnant or just gave birth. Maternal mortality (i.e., deaths during pregnancy or in the early postpartum period) increased by 18% in 2020, according to data from the National Center for Health Statistics, exceeding the ~16% increase in overall US mortality in 2020. Yet according to a new analysis from the University of Maryland and Boston University, the maternal death rate after the start of the COVID-19 pandemic was even higher, and disproportionately impacted Black and non-white Hispanic mothers.
A research letter published in JAMA Network Open by Marie Thoma in the UMD School of Public Health and Eugene Declercq in the BU School of Public Health compared maternal mortality data from 2018-March 2020, when the pandemic began, to April-December 2020. Overall, they found large increases in maternal death (33%) and late maternal deaths (41%) after March 2020 compared with before the pandemic, and conspicuous increases among Black and Hispanic mothers.
“The increase was really driven by deaths after the start of the pandemic, which are higher than what we see for overall excess mortality in 2020,” said Dr. Thoma, assistant professor of family science in the UMD SPH. The study also showed that existing and new disparities emerged after the pandemic with a 40% jump among already high rates for non-Hispanic Black women and a 74% jump among formerly lower rates in Hispanic women.
Strikingly, said Dr. Declercq, professor of community health sciences at BUSPH, “for the first time in more than a decade, the maternal mortality rate for Hispanic women during the pandemic was higher than that for non-Hispanic white women, a shift that may be related to COVID and deserves greater attention moving forward.”
COVID-19 was listed as a secondary cause of death in 14.9% of maternal deaths in the last nine months of 2020, with it being a contributing factor for 32% of Hispanic, 12.9% of Black and 7% of non-Hispanic white women giving birth.
In their analysis of causes of maternal death, they found the largest increases were due to conditions directly related to COVID-19 (respiratory or viral infection) and conditions made worse by COVID-19 infection, such as diabetes or cardiovascular disease. However, interruptions to the health care system could have led to delayed prenatal care that could have meant that risk factors for pregnancy complications went undetected.
“We need more detailed data on the specific causes of maternal deaths overall and those associated with COVID-19,” Dr. Thoma said. “Potentially we could see improvements in 2021 due to the rollout of vaccines, as well as the extension of postpartum care provided for Medicaid recipients as part of the American Rescue Act of 2021 in some states. We’re going to continue to examine this.”
Journal
JAMA Network Open
Method of Research
Data/statistical analysis
Subject of Research
People
Article Title
All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic
U.S. FDA will decide on redesigned COVID vaccines by early July
U.S. regulators plan to decide by early July on whether to change the design of COVID-19 vaccines this fall in order to combat more recent variants of…
U.S. FDA will decide on redesigned COVID vaccines by early July
June 28, 2022, 9:58 AM EDT
By Michael Erman
June 28 (Reuters) – U.S. regulators plan to decide by early July on whether to change the design of COVID-19 vaccines this fall in order to combat more recent variants of the coronavirus, with hopes of launching a booster campaign by October, a top Food and Drug Administration official said on Tuesday.
“The better the match of the vaccines to the circulating strain we believe may correspond to improve vaccine effectiveness, and potentially to a better durability of protection,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said at a meeting of outside advisers to the regulator.
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration
The committee is scheduled to vote on a recommendation on whether to make the change later on Tuesday.
The updated shots are likely to be redesigned to fight the Omicron variant of the coronavirus, experts say. read more The exact composition of the retooled shots and whether they also will include some of the original vaccine alongside new components will be considered at the meeting.
Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Novavax Inc. (NVAX.O) are scheduled to present data at the meeting. All three companies have been testing versions of their vaccines updated to combat the BA.1 Omicron variant that was circulating and led to a massive surge in infections last winter.
Both Moderna and Pfizer with partner BioNTech (22UAy.DE) have said that their respective redesigned vaccines generate a better immune response against BA.1 than their current shots that were designed for the original virus that emerged from China.
They have said that their new vaccines also appear to work against the more recently circulating BA.4 and BA.5 Omicron subvariants, even though that protection is not as strong as against BA.1.
Experts also want to know if the new shots will boost protection against severe disease and death for younger, healthier people or merely offer a few months’ additional safeguard against mild infection.
Scientists who have questioned the value of booster shots for young and healthy people have said a broad campaign is not needed with an updated shot either.
Other experts have championed any additional protection new vaccines may offer.
Reporting by Michael Erman Editing by Bill Berkrot and Bernadette Baum
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
